Subject(s)
Escherichia coli Infections/microbiology , Escherichia coli/enzymology , beta-Lactamases/isolation & purification , Adult , Anti-Bacterial Agents/pharmacology , Drug Resistance, Multiple, Bacterial , Escherichia coli/drug effects , Female , France , Humans , Microbial Sensitivity Tests , Middle AgedABSTRACT
TEM-89 (CMT-3) is the first complex mutant beta-lactamase produced by a clinical strain of Proteus mirabilis (strain Pm 631). This new enzyme, which has a pI of 6.28, is derived from TEM-3 and has a single amino acid substitution also encountered in TEM-59 (inhibitor-resistant TEM beta-lactamase IRT-17): Ser-130 to Gly. TEM-89 hydrolyzed penicillins to the same extent that TEM-3 did but lost almost all hydrolytic activity for cephalosporins and, like TEM-59, was highly resistant to inhibitors.
Subject(s)
Proteus Infections/microbiology , Proteus mirabilis/enzymology , Proteus mirabilis/genetics , beta-Lactamases/genetics , beta-Lactamases/metabolism , Amino Acid Substitution , Conjugation, Genetic , Escherichia coli/genetics , Humans , Isoelectric Focusing , Kinetics , Molecular Sequence Data , Mutation/genetics , Plasmids/genetics , Proteus mirabilis/drug effects , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
The epidemiological study of several multidrug-resistant Enterobacteriaceae isolated from five patients demonstrated in vivo dissemination of a 100-kb plasmid encoding the extended-spectrum beta-lactamase TEM-24 from a clonal strain of Enterobacter aerogenes to different strains of Klebsiella pneumoniae, Escherichia coli, Proteus vulgaris, Proteus mirabilis, and Serratia marcescens.
